Login
Zenas BioPharma, Inc. logo

Zenas BioPharma, Inc.

zenasbio.com

What Do They Do?

Develops drug candidates for autoimmune and inflammatory diseases, including antibody and oral therapies for patients with multiple sclerosis and other immune conditions.

How Do They Make Money?

The company can earn revenue by licensing drug-candidate rights: a partner pays an upfront fee, with additional payments tied to development or commercial milestones and royalties on sales.

FY2025 revenue

Who Are Their Customers?

Bristol Myers Squibb holds licensed rights to develop and commercialize obexelimab in several markets, and Zai Lab has an exclusive sublicense for ZB001 in greater China. If products are approved, Zenas plans to sell directly in the U.S. and Europe and use third parties in Asia and other regions.

Do Revenues Turn Into Profits?

No. It lost $377.7M in FY2025.

Operating income, FY2025
−3831% of revenue
▼ −134% (Loss) vs FY2024 (−$163.9M, −3278%)
Net income, FY2025
−3777% of revenue
▼ −141% (Loss) vs FY2024 (−$157M, −3140%)
Free cash flow, FY2025
−1724% of revenue
▼ −44% (Loss) vs FY2024 (−$119.8M, −2396%)

How Are They Changing?

Since the FY2025 annual report
Latest quarter: Q3 FY2026, the three months to Sep 30, 2026
Revenue
  • Aug 13, 2026 CFO to transition to strategic-adviser role The CFO is set to move to a strategic-adviser role to the Board Chair at the end of September.

Who Do They Compete With?

Competes with Amgen, Sanofi, Acepodia, F. Hoffmann-La Roche, Novartis, TG Therapeutics, Biogen, Bayer, Teva Neuroscience, Bristol Myers Squibb, Genzyme, Banner Life Sciences, Janssen Pharmaceuticals, Cycle Pharmaceuticals, Immunic Therapeutics, AB Science, GSK, AstraZeneca, RemeGen, and UCB

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Premium Feature

This feature requires a premium subscription to unlock unlimited historical data and advanced analysis tools.

Premium includes:

  • Unlimited historical financial data
  • Advanced analytics and insights
  • Priority support